Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters

European Journal of Cancer

Volumn 45, Issue 9, 2009, Pages 1664-1672

  Ebelt, Kathleen ^a,b   Babaryka, Gregor ^c   Frankenberger, Bernhard ^a   Stief, Christian G ^d   Eisenmenger, Wolfgang ^c   Kirchner, Thomas ^c   Schendel, Dolores J ^a   Noessner, Elfriede ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

B7 H1; Exhausted lymphocytes; FOXP3; PD 1; Tregs; Tumour infiltrating lymphocytes

Indexed keywords

B7 ANTIGEN; B7 H1 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; PERFORIN; PHOSPHODIESTERASE I; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IMMUNOREGULATION; LYMPHOCYTE; LYMPHOCYTE FUNCTION; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE;

AGED; ANTIGENS, CD; ANTIGENS, NEOPLASM; APOPTOSIS REGULATORY PROTEINS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 65849449107     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.02.015     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 1 (2007) 43-66
2. Hsing A.W., Tsao L., and Devesa S.S. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer (Pred Oncol) 85 (2000) 60-67
3. Tsuta K., Ishii G., Kim E., et al. Primary lung adenocarcinoma with massive lymphocyte infiltration. Am J Clin Pathol 123 4 (2005) 547-552
4. Waldner M., Schimanski C.C., and Neurath M.F. Colon cancer and the immune system: the role of tumor invading T cells. World J Gastroenterol 12 45 (2006) 7233-7238
5. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 (2001) 380-384
6. Galon J., Costes A., Sanchez-Gabo F., Kirilovsky A., et al. Type, density and location of immune cells within human colorectal tumours predict clinical outcome. Science 313 5795 (2006) 1960-1964
7. Suri-Payer E., and Fritzsching B. Regulatory T cells in experimental autoimmune disease. Springer Semin Immunopathol 28 1 (2006) 3-16
8. Dejaco C., Duftner C., Grubeck-Loebenstein B., and Schirmer M. Imbalance of regulatory T cells in autoimmune diseases. Immunology 117 3 (2006) 289-300
9. Knutson K.L., Disis M.L., and Salazar L.G. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother 56 3 (2007) 271-285
10. Piermas S.J., Welters M.J., and van der Burg S.H. Tumor-specific regulatory T cells in cancer patients. Human Immunol 69 4-5 (2008) 241-249
11. Tamura H., Ogata K., Dong H., and Chen L. Immunology of B7-H1 and its roles in human diseases. Int J Hematol 78 (2003) 321-328
12. Barber D.L., Wherry E.J., Masopust D., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 7077 (2006) 682-687
13. Day C.L., Kaufmann D.E., Kiepiela P., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 7109 (2006) 350-354
14. Nishimura H., Okazaki T., Tanaka Y., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor deficient mice. Science 291 5502 (2001) 319-322
15. + lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 68 1 (2008) 1-10
16. + regulatory T cells. Nat Immunol 4 4 (2003) 330-336
17. Brunkow M.E., Jeffery E.W., Hjerrild K.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27 1 (2001) 68-73
18. + Tregs impinge on autoimmune diabetes. J Exp Med 202 10 (2005) 1387-1397
19. Bennett C.L., Christie J., Ramsdell F., Ramsdell F., and Brunkow M.E. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27 1 (2001) 20-21
20. Sfanos K.S., Bruno T.C., Maris C.H., et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14 11 (2008) 3254-3261
21. + regulatory T cells mediate immunsuppression in prostate cancer. Clin Cancer Res 13 23 (2007) 6947-6958
22. Miller A.M., and Pisa P. Tumor escape mechanism in prostate cancer. Cancer Immunol Immunother 56 1 (2007) 81-87
23. Bronte V., Kasic T., Gri G., et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 201 8 (2005) 1257-1268
24. Hirano F., Kaneko K., Tamura H., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65 3 (2005) 1089-1096
25. Dong H., Zhu G., Tamada K., and Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5 12 (1999) 1365-1369
26. Wintterle S., Schreiner B., Mitsdoerffer M., et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63 21 (2003) 7462-7467
27. Konishi J., Yamazaki K., Azuma M., Kinoshita I., Dosaka-Akita H., and Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10 15 (2004) 5094-5100
28. Thompson R.H., Gillett M.D., Cheville J.C., et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101 49 (2004) 17174-17179
29. Thompson R.H., Kuntz S.M., Leibovich B.C., et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66 7 (2006) 3381-3385
30. Roth T.J., Sheinin Y., Lohse C.M., et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 67 16 (2007) 7893-7900